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INTRODUCTION 
Peroxisomes are subcellular respiratory organelles characterized by the 
presence of flavin oxidases and catalase (1-3). Their existence was first 
reported in 1954 by Johannes A.G. Rhodin from electron micrographs of 
mouse kidney tissue (4,5). Rhodin called the organelle a microbody. The 
organelle was described in rat liver cells two years later. In the mid-
1950s, after refinement of isolation techniques, P. Baudhuin and H. 
Beaufay described the presence of the enzyme uricase, or urate oxidase, in 
the organelle (4,5). They termed the organelle the uricorisome. During the 
following 10 years, the emphasis of studies dealing with the peroxisome 
focused on mammalian liver and kidney. This resulted in the discovery 
that the particle contains several oxidases, and most significantly, catalase. 
In the late 1960s, Christian deDuve proposed that the organelle be called a 
peroxisome to reflect the central role played by catalase (1). 
Electron microscopy studies of liver reveal the peroxisome to be a 
spherical or dumbell shaped particle approximately 0.05 to 1.50 ]Lim in 
diameter. The size and shape of the organelle will depend on the species 
and tissue within which it is located (6-9). The peroxisome may be 
connected to other peroxisomes as part of an interconnected network (10). 
This observation, however, has not been substantiated. 
2 
Peroxisomes are bounded by a single trilaminar membrane and possess 
a granular matrix. In liver, the organelle normally exhibits an electron 
dense anucleoid crystalline core (6,7,11). In some species, such as the rat, 
the core is composed of insoluble urate oxidase. In other species, such as 
man, it may be catalase. 
The peroxisome tends to be smaller in extrahepatic tissues, 
approximately 0.15 to 0.25 ^m in diameter. The organelle lacks a central 
core and has a membrane which has been reported to be continuous with 
the endoplasmic reticulum (12,13). To reflect the smaller size, the 
organelle has been referred to as microperoxisome. 
The peroxisome's distribution in nature is wide. Since the mid-1960s 
a variety of species have been studied. This has resulted in the belief that 
peroxisomes are present universally throughout the eukaryotic kingdom 
(1,6,7). They have been described in a number of tissues as well. The list 
includes, but is not limited to, striated muscle, cardiac muscle, sebaceous 
glands, smooth muscle, brown fat, white fat, germinal tissue, epithelial 
tissue, bladder tissue, yolk sacs, prostate glands, Schwann cells, lymphoid 
tissue, connective tissue, mammary tissue, intestinal tissue, lungs, 
chondroblasts, nervous tissue, spleen, thymus, blood vessels, kidney, 
adrenal tissue, brain, and liver (7,8,14). 
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Although the organelle is widespread in nature, astonishing differences 
in enzyme composition exist. The peroxisomal enzyme repertories vary, 
depending on the species and the tissue one is investigating (1). Variation 
in enzymatic composition has been noted in response to changes in 
substrate availability and stage of development as well (11,15,16,17,18). 
This diversity is totally unknown for any other kind of organelle and has 
made it difficult to attribute a function or assign a unified conceptual 
arrangement into which these variations can be placed. Thus, a function 
for the organelle has yet to be assigned. 
P-Oxidation 
The only complete metabolic pathway described in the mammalian 
organelle is ^-oxidation. Previously, P-oxidation was believed to be 
associated only with the mitochondria and the glyoxisome. Comparison of 
mitochondrial P-oxidation and peroxisomal P-oxidation has been carried 
out by several investigators who have demonstrated that peroxisomes 
contain no energy-coupled electron transport chain (1,19-25). 
Peroxisomal p-oxidation is also cyanide-insensitive and results in the 
generation of heat, water, short-chain acyl-CoA (octanyl-CoA and shorter), 
reduced nicotinamide adenine dinucleotide (NADH), and hydrogen 
peroxide from substrates passing through the pathway. 
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The fate of the products of peroxisomal p-oxidation has not been 
established, Acyl-CoA is believed to be funneled to the mitochondria for 
the production of adenosine triphosphate (16,19,21). Reduced 
nicotinamide adenine dinucleotide may function in providing a pool of 
nucleotides for other cell processes and in maintaining the cell's redox 
potential. The NADH may be transported to the mitochondria via a 
specific shunt such as the dihydroxyacetone phosphate reductase-
glycerophosphate dehydrogenase electron shuttle (1,16,21,26,27,28). 
Physical characteristics of the enzymes are pathway-specific as well 
(1). This probably accounts for the different substrate specificities, pH 
optimum, and cofactor requirements observed for the pathways. 
Peroxisomes are characterized as having flavin oxidases, which require 
FMN or FAD as prosthetic groups (1,29). Peroxisomal enzymes have a 
pH optimum around 8.5 as compared to the lower pH profiles in other 
subcellular compartments (1,29,30). Peroxisomal enzymes have different 
amino acid compositions, structural arrangements, and kinetic parameters 
as compared to their mitochondrial counterparts (1,30,31,32,33,34,35). 
As a result, the enzymes of peroxisomal P-oxidation differ in substrate 
specificity from those of the mitochondria. Peroxisomes prefer long-chain 
fatty acids and may not oxidize any smaller than octanyl-CoA 
(16,17,25,36,37). The peroxisomal system preferentially oxidizes fatty 
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acids of 14 to 16 carbons in length. Mitochondria apparently prefer 
short-chain fatty acids. Dicarboxylic acids and unsaturated fatty acids are 
oxidized in the peroxisome as well (38,39,40). 
It can be proposed that since peroxisomes possess a p-oxidation chain, 
do not produce useful energy, prefer medium to long-chain fatty acids as 
substrates, and result in the production of short-chain acyl-CoA, they 
function to complement the mitochondria in their metabolic role. The 
peroxisome may be providing a substrate source to the mitochondria which 
would not otherwise be available. The peroxisome may also help in 
maintaining the cell's state of homeostasis by preventing the build-up of 
toxic substances such as long- and very-long chain fatty acids. These 
hypotheses are supported by the fact that high fat diets, prolonged vitamin 
E deficiency, starvation, and exposure to cold result in increased 
peroxisomal p-oxidation rates (17,41,42,43,44). Peroxisomal P-oxidation 
is very active in the perinatal period as well (45). Peroxisomal 
proliferation occurs in some species in response to treatment with certain 
drugs and exposure to some environmental toxicants. These results may 
indicate that the peroxisome plays a role regulating energy balance in the 
cell during highly stressful periods of life. 
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However, it has been estimated that, in rodents, the maximal contribution 
of the peroxisome to the cell's total capacity for P-oxidation never exceeds 
10-30% (1,32). Data from other species are limited. 
Cholesterol Metabolism 
The ability of the peroxisome to oxidize cholesterol has recently been 
reported. It has been demonstrated that cholesterol can be oxidized 
through a hydroxylated intermediate, via peroxisomal P-oxidation, to 
propionate and cholic acid (46). It was further demonstrated that cholic 
acid can be conjugated to glycine and taurine in the organelle to form the 
bile acids taurocholic and glycocholic acid (47). Treatment of rodents 
with cholestyramine, a drug which binds bile acids in the intestines, results 
in an induction of peroxisomal P-oxidation (48). A peroxisomal 
hydroxymethyl glutaryl Co-A reductase has been identified too, suggesting 
that the peroxisome could produce cholesterol as well as oxidize it (49,50). 
A peroxisomal role in cholesterol metabolism seems likely. 
Glycerolipid Synthesis 
Peroxisomes may play a crucial role in the syntliesis of the 
plasmalogens. Peroxisomes have been shown to contain a 
dihydroxyacetone phosphate ac}'.transferase (1). This enzyme is an 
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obligatory step in the synthesis of the ether glycerolipids, or plasmalogens 
(51). Much of the activity of this enzyme has been demonstrated to be in 
the peroxisome and it is inducible by clofibrate (51,52). The functions of 
plasmalogens are unknown. They are present in all cell types and are 
especially abundant in electrically active tissues such as nervous tissue and 
muscle (52). Thus, it is believed they are important in transmembrane 
movement of electrolytes. Individuals deficient in peroxisomes contain 
extremely low levels of plasmalogens (53). These individuals suffer from 
lack of muscle tone and mental retardation which conceivably could be 
due to plasmalogen deficiency (51). It appears that the peroxisome does 
play an important role in lipid metabolism but its full nature remains 
unclear. 
Peroxisomes and Hypolipidemic agent 
The belief of a peroxisomal role in lipid metabolism has led 
investigators to examine the relationship of the organelle to serum and 
organ cholesterol and triglyceride levels. Cholesterol and triglycerides 
have been implicated as possible causative agents in several pathological 
states, especially in this nation's number one cause of death, heart disease 
(43,49,50,54). 
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Several drugs are routinely used to control serum triglyceride levels in 
man and animals. Some have been noted to cause an induction of selected 
peroxisomal and nonperoxisomal enzymes. A proliferation of peroxisomes 
occurs as well as proliferation of the smooth endoplasmic reticulum 
(SER), and to a lesser extent, mitochondria (1). These data, however, 
come predominantly from the rat and mouse (55-63). Few data are 
available on these compound's effects in man or animals other than 
rodents. The number of compounds known to affect the rodent peroxisome 
is large and constantly increasing. They are collectively referred to as 
peroxisome proliferators and encompass a variety of industrial uses such 
as in plasticisers, pesticides, prescription drugs, and some over-the-counter 
analgesics. One may conclude that human exposure to these chemicals is 
probably high. 
Clofibrate (p-chlorophenoxyisobutyric acid) is probably the most 
widely used hypolipidemic drug available today, and forms the core of a 
number of structurally related peroxisome proliferators. Clofibrate has 
been shown to cause peroxisome proliferation, hepatomegaly, increases in 
enzyme activity, and increased mitochondrial p-oxidation (56,57,58,60, 
64,65,66). Fenofibrate (isopropyl[4(p-chlorobenzoyl)-2-phenoxy-2-methyl] 
propionate), a derivative of clofibrate, also causes a marked proliferation 
of peroxisomes in rats, mice, and hamsters. Hepatomegaly has been 
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reported in some species (56,65,66). Methyl clofinapate (2-methyl-[4-(p-
chlorophenol)phenoxy]methyl propionate), a methylated derivative of 
clofibrate, also possesses effects similar to clofibrate, but is much more 
potent in rodents. Simfibate (1,3-propenediol-bis (2-p-chlorophenoxy) 
isobutyrate) shows little effect on hepatic lipid levels yet increases cyanide 
insensitive fatty acyl-CoA oxidation and carnitine acetyl transferase 
activity (58,65,66). Pyrinixil (BR-931; 4-chloro-6-(2,3-xylidino)-2-
pyromidenylthio-(N-beta-hydroxyethyl) acetamide) behaves similarly to 
fenofibrate (54,63,64). A new hypolipidemic compound, POCA (ethyl-2-
[5(4-chlorophenyl) pentyl] oxiran-2-carboxylate), causes a 2.15-fold 
increase in peroxisomal numbers and a decrease in their average size from 
0.36 to 0.31 nm in the rat hepatocyte (56). It results in a 3-fold increase 
in the capacity for P-oxidation as well. Most importantly, it tends to 
inhibit mitochondrial P-oxidation at carnitine palmitoyl transferase. The 
compound tends to be effective only in starved rats, however, and not in 
fed rats. LK-903 (alpha-methyl-p-myristyroxycinnnamic acid-1-
monoglycerol) also possesses hypolipidemic activity similar to clofibrate 
but does not result in hepatomegaly. It does increase the activity of 
catalase, D-amino acid oxidase, urate oxidase, and p-oxidation (60). 
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Acetysalicyclic acid, a common over-the-counter analgesic, also lowers 
serum triglyceride levels. Induction of peroxisomal enzymes and 
peroxisome proliferation has been reported in rats (52). Hepatomegaly has 
been noted. No information is available on its effect on non-rodent 
peroxisomes. 
Certain environmental contaminants also possess hypolipidemic 
activity (62,63). Phthalate esters are plasticizers that have uses in different 
industrial processes. Large amounts of these substances have been 
reported to occur in water, soil, and the food chain (67). Plasticizers 
commonly used in industry such as di-(2-ethylhexyl) phthalate have been 
shown to cause proliferation of hepatic peroxisomes in the rat (62,63). 
Proliferation of mitochondria has been described as well (68). Increases in 
liver weight of up to 50% have been observed in association with the 
hypolipidemic action of these compounds. Phenoxyacid herbicides have 
been reported to result in similar effects (69). 
Peroxisomes and Oxygen Toxicity 
Long-term treatment of rodents with peroxisome proliferators results in 
the development of hepatocellular carcinomas. It has been proposed that 
these drugs, as a class, are carcinogenic (70). Phthalate esters have been 
observed to induce hepatocellular carcinomas in both F-344 rats and 
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B6C3F1 mice (71). Treatment with Wyl4,643, an experimental 
hypolipidemic drug which is structurally unrelated to clofibrate, has been 
shown to induce hepatic carcinomas in male F-344 rats (72). These 
studies show that peroxisome proliferators are carcinogenic in rodents but 
the mechanism of carcinogenesis still remains unclear. 
Investigations to elucidate the etiology of hypolipidemic drug-induced 
carcinomas demonstrate that peroxisome proliferating agents are not 
mutagenic. Studies in the lymphocyte [^H] thymidine assay and 
mutagenesis assay show that the drugs do not form DNA adducts or cause 
genetic damage directly (73). The mechanism proposed to be responsible 
for the hepatocellular carcinoma development in rodents involves the 
generation of excessive hydrogen peroxide (H2O2). Reddy et al. (70) have 
suggested that the proliferative action of these agents on peroxisomes 
causes the generation of excessive amounts of reactive oxygen species. 
These free radicals may attack membrane lipid components, proteins, and 
nucleic acids - ultimately resulting in cancer. The concentration of 
catalase in the peroxisome and the kinetics of the enzyme, however, do 
not support this. 
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Detoxification Capacity of the Peroxisome 
Cells have evolved a number of mechanisms to deal with oxidative 
stress. Catalase is the standard marker enzyme for the peroxisome and 
accounts for approximately 60% of the total protein present in the 
organelle (3). Catalase functions to metabolize to H2O, O2, and 
heat. Investigations into the kinetics of this enzyme show it to be very 
active, possessing a rate constant of 10^ sec'^ mole"^ (74). 
Reactive oxygen species, which escape the peroxisomal catalase, can 
attack lipid components of the cell resulting in the generation of epoxides. 
These, in turn, may interact with other cell macromolecules, adversely 
affecting their function. Epoxide hydrase hydrates epoxides to more stable 
dihydro-diols. Waechter et al. (75) have reported that this enzyme is 
probably present in the peroxisome instead of the mitochondria as 
previously believed. Seventy percent of the enzymes activity was found to 
be located in the peroxisome. 
Aldehyde dehydrogenase (ALDH), with a high for acetaldehyde, 
has been partially purified from the peroxisome of rats (76). Aldehydes 
formed as oxidation products of lipids can also interact with 
macromolecules and are reduced to the more stable carboxylic acid by this 
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enzyme, effectively, being detoxified. The high isozyme of ALDH in 
the rodent peroxisome has been shown to be inducible by clofibrate (77). 
Superoxide dismutase scavenges the superoxide anion (Og"), reducing 
it to the more stable hydrogen peroxide which can then be destroyed by 
catalase or glutathione peroxidase (78). Murphy and Gee (personal 
communication, Dr. P.A. Murphy, Iowa State University) have found that 
superoxide dismutase may be associated with the peroxisome. Few 
studies have been conducted to examine this enzyme's response to 
peroxisome proliferating conditions. Some increase in activity has been 
noted, but decreases in activity have been reported as well. 
Antioxidants are also present in normal cells. Compounds such as 
vitamin E, glutathione, ascorbic acid, and vitamin A are present to remove 
any reactive oxygen moiety generated in the metabolic processes. 
It would seem that adequate controls are present in the cell to limit the 
amount of free radicals generated, even during periods of peroxisome 
proliferation. Data on the effects of hypolipidemic compounds on these 
cellular constituents are lacking. The exact mechanism of peroxisome 
proliferation and peroxisome-related tumorogenesis remains to be 
elucidated. 
• " ! 
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Phylogenetic Factors and Peroxisome Proliferation 
The primary site of toxic action in rodents from hypolipidemic drugs 
is the liver. The specific lesions reported in the literature tend to depend 
on which species were used in the experiment. Commonly reported 
effects usually consist of a dose-dependent liver enlargement 
(hepatomegaly) with minor histological changes and elevated serum 
transaminase activity (3,63,65,66,79,80). 
Ultrastructurally, peroxisome numbers increase and changes in 
organelle size have been noted after treatment with peroxisome 
proliferators (65,66,71,79,80). Proliferation of smooth endoplasmic 
reticulum and rough endoplasmic reticulum (RER) accompany these 
changes, with dilatation of the SER and RER membranes being common 
(65,66,79). Administration of hypolipidemic agents has been reported to 
cause depressed microsomal enzyme activities (65,79). 
Some researchers have reported elevated microsomal enzyme activities as 
well (65,79). Slight increases in the cytochrome P-450 mixed function 
oxidases have been noted in some studies, but detailed data are lacking 
(65,79). 
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Lazarow et al. (59) have compared the response of several species to 
treatment with hypolipidemic drugs and have shown that induction of 
peroxisomal P-oxidation does not obligatorily include gross hepatomegaly 
or other alterations of peroxisomes. In a related study, hypolipidemic 
drugs resulted in peroxisomal proliferation in dogs and hamsters, but not 
in primates or guinea pigs (81). 
Studies of peroxisomes in humans are severely limited. Human and 
rodent liver differ in a number of significant ways, especially in enzyme 
composition (3). No hepatomegaly was seen in primates or man after 
treatment with clofibrate, fenofibrate, or nafinopen (65,79). There did 
appear to be a slight tendency for the reduction of fatty infiltration of the 
liver, and liver glycogen levels tended to decrease also (65,79). No 
peroxisome proliferation has been reported in primates or man after 
exposure to these drugs at doses equivalent to those administered to 
rodents. In a separate study, isolated human hepatocytes were insensitive 
to levels of trichloroacetic acid which resulted in peroxisome proliferation 
in rat hepatocytes and mouse hepatocytes (82). Peroxisome proliferation in 
primates has been reported at exceedingly high dosages of these drugs, 
however (83,84). It would seem, then, that effects of peroxisome 
proliferators are not uniform across all species. "Higher animals" may be 
less sensitive to peroxisome proliferators than are rodents because of 
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intrinsic metabolic differences (85). The direct application of rodent 
databases to risk assessment must be questioned. Detailed data on the 
metabolism of the peroxisome of animals more likely to reflect human 
peroxisomal metabolism need to be collected. 
Peroxisomes in Disease 
Very little is known about peroxisomes in disease. Peroxisomes do 
appear to play a role in some disease states (86). Peroxisomes tend to 
become more abundant and assume a perinuclear configuration in human 
cholestatic and cirrhotic livers (86). Decreased diaminobenzidine staining, 
a histochemical stain specific for catalase, was common in the diseased 
tissue when compared to normal liver. These reactions were found in 
human neoplasms as well (87). Humans bom with Zellweger's 
cerebrohepatorenal syndrome have been demonstrated to possess no 
peroxisomes in the liver tissue (88,89). Victims of this congenital disease 
usually do not survive past six months of age. Increased peroxisomal 
degradation has been implicated in acute hepatic failure in partial ornithine 
transcarbamylase deficiency also (90). An increased number of hepatic 
peroxisomes have been reported in several other pathological states such 
as alcoholic liver disease, certain infectious diseases, toxicosis, and Reye's 
syndrome (5,8,10,49). In addition, Stemlieb and Quintana (9) found 
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significant alterations in peroxisomal size and electron density in 14 out of 
19 of the pathologic human livers that they examined. These livers were 
from patients afflicted with hepatitis induced by drug therapy, cholestasis, 
and Wilson's disease. Data concerning biochemical alterations are lacking. 
Research Rationale 
The importance of peroxisomes to the cell still remains to be 
elucidated. A peroxisomal role in lipid metabolism does seem likely. 
Studies on humans have been sparse, and the ability to extrapolate data 
from rodents to man is questionable. In view of the fact that peroxisome 
proliferators are associated with neoplasia in rodents and are affected in 
some disease states in humans, it would be desirable to develop a more 
complete understanding of the metabolic function of the organelle. It is 
also necessary to establish how peroxisomal metabolism differs among 
species, specifically if peroxisomes in phylogenetically higher animals are 
sensitive to agents that proliferate peroxisomes in rodents. Mechanistic 
differences among species in peroxisome proliferation should be elucidated 
to determine if a risk to humans exist. 
Species specificities can arise via a number of different mechanisms. 
Absorption and distribution kinetics of peroxisome proliferators may vary. 
Sites of action may differ. 
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Receptors in target tissues may vary in quantity or form. A cytosolic 
receptor for nafinopen has been described (91). 
Akbar et al. (92) have demonstrated that clofibrate decreases the activity 
of adenylate cyclase in some cell types, possibly by a receptor-mediated 
process. Detoxification pathways and mode of elimination may also be 
species specific. Intrinsic differences in sensitivity to peroxisome 
proliferation may also exist. 
In the past, research utilizing animals other than rodents has been 
difficult because of spatial needs, expense, long generation-time, and 
handling requirements. With the advent of tissue culture methodology, 
these logistical problems can be overcome. It would be beneficial to apply 
this technology to answer questions dealing with interspecies differences in 
peroxisomal metabolism. New and valuable information could be 
contributed to the literature on this topic if tissues from animals that 
physiologically resemble man were studied. Primary porcine hepatocyte 
cultures would be such a model. 
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Cell culture will allow investigators to eliminate the effects of route 
and kinetics of absorption and distribution. Cell culture can be used to 
define target cells and the effects of peroxisome proliferators in those 
cells. Cell culture also offers a means of clarifying the contribution of the 
organelle to cellular lipid metabolism. Specific substrates can be added to 
the growth matrix for the study of carbon shunting in metabolism. 
Metabolic pathways can be inhibited or activated through the use of 
appropriate effectors. In short, cell culture offers unlimited opportunities 
for the study of peroxisomal metabolism and as yet has been under­
utilized. 
The purpose of this project then would be to examine the applicability 
of porcine hepatocyte tissue culture to studies involving peroxisomes, and 
to investigate the response of superoxide dismutase, aldehyde 
dehydrogenase, mitochondrial P-oxidation, and peroxisomal P-oxidation to 
the administration of clofibric acid, a known peroxisome proliferator. 
Explanation of Dissertation Format 
The dissertation is divided into two parts, each being a complete paper 
already submitted to a professional journal. Part I is a report of an 
isolation protocol for porcine hepatocyte peroxisomes and the examination 
of the contribution of peroxisomal P-oxidation to lipid metabolism. 
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It also describes the localization of an isozyme of aldehyde dehydrogenase 
in the organelle. Part II outlines a procedure for the isolation and growth 
of viable porcine hepatocytes. It describes the effects of clofibric acid on 
the isolated cells and the presence of a peroxisomal superoxide dismutase. 
Species-related factors in peroxisomal metabolism are discussed. 
21 
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PART I. 
SUBCELLULAR LOCALIZATION AND CAPACITY OF 
P-OXIDATION AND ALDEHYDE DEHYDROGENASE 
IN PORCINE LIVER 
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ABSTRACT 
Porcine hepatocyte organelles were separated by isopycnic sucrose 
gradient centrifugation from livers of 6-month-oId Yorkshire pigs. The 
presence of a peroxisomal palmityl-CoA oxidizing system and a 
peroxisomal NAD:aldehyde dehydrogenase (ALDH) with high for 
acetaldehyde was demonstrated. Peroxisomal palmitate oxidizing capacity 
was found to be equal to that of the surviving mitochondria. The high 
isozyme of ALDH was located mainly in the mitochondria (54%), with a 
significant portion in the peroxisome. Remaining activity was distributed 
among the microsomes (8.3%) and cytosol (4.6%). The low isozyme 
was confined almost exclusively to the mitochondria. ALDH may exist in 
the peroxisome as a detoxification mechanism and contribute to shorter 
half-lives of reactive aldehydes in the cell. Species differences are 
discussed. 
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INTRODUCTION 
Peroxisomes are small membrane-bound organelles. They have been 
identified in species ranging from yeast to man (1). The role of the 
peroxisome in the cell is unknown. A peroxisomal P-oxidation pathway 
exists in the species studied and a role in lipid metabolism has been 
proposed( 2-4). 
Perturbations in peroxisomal numbers and enzyme activity profiles, 
have been effected by treatment with several xenobiotics. Treatment with 
compounds such as the hypolipidemic agents, clofibrate and its analogs, 
di-(ethylhexyl) phthalate, acetylsalicyclic acid, and phenoxyacid herbicides 
results in profound increases in both peroxisomal numbers and selected 
enzyme activities. A concomitant decrease in serum triglyceride levels has 
been observed as well (5-12). Long-term treatment of rats with 
peroxisome proliferators results in development of hepatocellular 
carcinomas (13). 
Few researchers have investigated peroxisomes in species other than 
rodents. An absence of peroxisome proliferation has been reported in 
several species (14), or may occur only at high xenobiotic concentrations 
(7,15). Mitochondrial p-oxidation is rarely mentioned in these studies. 
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thus the interaction of the two pathways is unknown in non-rodent species. 
Recently, the high isozyme of NAD:aldehyde dehydrogenase 
(ALDH) has been partially purified from the rat hepatocyte peroxisome 
(16). The existence of a peroxisomal ALDH in species other than rodents 
has not been reported. Species differences in the activity and subcellular 
distribution of P-oxidation, ALDH, or other detoxification systems may 
account for the response to peroxisome proliferators and, as yet, have not 
been explored. The purpose of this paper is to report the presence of a 
peroxisomal ALDH in the porcine hepatocyte and to report the relationship 
of peroxisomal p-oxidation to mitochondrial p-oxidation in the porcine 
liver. 
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MATERIALS AND METHODS 
Animals 
Liver sections were obtained from 6 to 8-month-old Yorkshire female 
and castrated male pigs immediately postmortem. Two pigs had ascarid 
scars in the liver. No significant difference (P>.10) existed between these 
livers and the other livers in enzyme profiles. 
The central lobe from each liver was removed and perfused with an 
ice-cold homogenizing buffer through a central vein. The perfusion was 
continued until the liver was tan in color. The perfused tissue was 
scissor-minced and homogenized (10% wt/v) with 1 stroke of a motor-
driven teflon Potter-Elvehjem tissue homogenizer at 100 RPM. The 
homogenization buffer consisted of 20 mM MOPS (Sigma Chemical Co.), 
pH 7.4, 0.25 M sucrose, and .10% ethanol. All operations were carried 
out on ice. 
The homogenate was centrifuged for 10 min at 750 z g to obtain the 
post-nuclear supernatant. This supernatant was layered onto a nonlinear 
sucrose gradient, ranging in density (20°C) from 1.08 g/ml to 1.28 g/ml. 
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Gradients were prepared 24 hr before use. Centrifugation was carried out 
using a Beckman SW28Ti rotor at 105,000 x g (4°C) in a Beckman L-2 
ultracentrifuge, for 3.5 hr. 
p-Oxidation and catalase activities were assayed on gradient fractions 
immediately upon completion of the centrifugation run. All other assays 
were performed on gradient fractions stored at -20°C. 
Enzyme Assays 
Organelles were identified by using the marker enzymes catalase (EC 
1.11.1.6) for peroxisomes, NAD:glutamate dehydrogenase (ECl.4.1.2) for 
mitochondria, and NADPH:cytochrome c reductase (EC 1.6.99.3) for 
endoplasmic reticulum (ER). Catalase (17) was assayed immediately after 
collection of the gradient fractions and its units correspond to mmoles 
H2O2 consumed/min. NAD:Glutamate dehydrogenase was assayed (18) as 
reported, with the following modifications. Fifty-five ng/ml antimycin A 
and 5 ng/ml rotenone were included in the assay buffer to inhibit NADH 
oxidase. Units correspond to nmoles NAD reduced/min. 
NADPH:Cytochrome c reductase was assayed as in (19). Units 
correspond to nmoles NADPH oxidized/min. 
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Mitochondrial p-oxidation was assayed (20) as palmityl-CoA-
dependent oxygen consumption, using a Clark-type electrode at 35°C. The 
oxygen concentration of air-saturated water was taken to be 231 |xM (21). 
The procedure was modified to include 100 |iM ATP and 0.5 mM DL (+) 
carnitine in the assay. Units correspond to nmoles O, consumed/min. 
Peroxisomal P-oxidation was measured (22) as |j,moles oxygen 
consumed. The assay was modified to contain 22 ng/ml antimycin A 
instead of KCN. Units correspond to nmoles O2 consumed/min. 
High and low isozymes of ALDH (EC 1.2.1.5 and EC 1.2.1.3) 
were assayed as reported by Koivula and Koivusalo (23). The substrate 
concentration used for the high isozyme was 5 mM acetaldehyde. The 
substrate concentration for the low isozyme was 0.05 mM 
acetaldehyde. Units correspond to nmoles NAD reduced/min. 
Protein was determined by the method of Lowry et al. (24). 
Sucrose density was determined using a Bausch and Lomb 
refractometer maintained at 20°C. 
Reaction rates are reported as measured for the gradients depicted in 
figure 1. Some data in table I were adjusted to per gram of liver in order 
to correct for differences in mitochondrial and peroxisomal fragility and to 
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make interspecies comparisons (25). For these adjustments, appropriate 
areas from the gradients were summed and adjusted to 100% recovery 
based on homogenate measurements. 
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RESULTS 
Organelle Isolation 
Figure 1 shows that particulate catalase banded with peak activity at a 
density of 1.22 g/ml. Catalase activity was spread throughout the higher-
density region of die gradient and was not confined to a sharp peak. 
Twenty-eight percent of the catalase activity was present in the major 
band. On the average, supernatant catalase accounted for 57.5% of the 
total catalase activity. We did not ascertain how much of the supernatant 
catalase activity was due to broken peroxisomes. Several attempts were 
made to reduce the overlap of the marker peaks. Variation in buffer, pH, 
and gradient shape did not improve organelle resolution (data not shown). 
Fifty percent of the homogenate catalase activity was recovered from the 
gradient. 
Peroxisomal ^-oxidation activity corresponded with the high-density 
particulate catalase activity. Ninety-nine percent of the activity was 
isolated in this band. Fifty-two percent of the P-oxidation activity was 
recovered from the gradient. 
37 
NAD:Glutamate dehydrogenase sedimented in a sharp band, with 
maxirad activity at a density of 1.18 g/ml. Seventy-nine percent of the 
NAD:glutamate dehydrogenase activity existed in this band. The catalase 
band contained 13.5% of the NADiglutamate dehydrogenase activity. The 
presence of NAD: glutamate dehydrogenase activity in the supernatant 
(5.4%) undoubtedly corresponds to broken mitochondria. Total GDH 
activity on the gradient was 75% of the homogenate. 
Mitochondrial ^-oxidation corresponds with the activity of 
NADiglutamate dehydrogenase. Mitochondrial p-oxidation sedimented to 
an equilibrium position, with peak activity at a density of 1.17 g/ml. A 
single band existed, with 94.7% of the activity present. No activity was 
detected in the cytosol. Forty percent of the homogenate activity was 
found on the gradient. 
Figure 1. Distribution of enzymatic activity between peroxisomes, 
mitochondria, endoplasmic reticulum, and cytosol from a 
representative sucrose density gradient prepared from porcine 
liver. NAD:Glutamate dehydrogenase is a marker for mitochondria. 
Catalase is the marker for peroxisomes. NADPH:Cytochrome c 
reductase is the marker for the ER. Assay methods are described 
in Materials and Methods. 
39 
Aldehyde Dehydrogenase 
high km 
low km 
C 
Glutamate Dehydrogenase 
E 300 
200 
201 Ï 20r B-O"""™" Catalase sp. act. 4 pero* 
mito 
3 
2 O 
O 
/ \ 
4000r ^ NAOPHCYTC Reductase density -il.SO =-lOOr 
1.20 o ë 3000 E 
E 1.10 2000 
o £ 
s 1000 
5 10 15 20 25 30 
Fraction (ml) Fraction (ml) 
40 
NADPHiCytochrome c reductase sedimented in a single large band to 
an equilibrium density of 1.14 g/ml. Fifty-four percent of the enzymatic 
activity occurred in this band. The NAD:glutamate dehydrogenase peak 
contained 28.9% of the NADPH:cytochrome c reductase activity, and 
4.8% was present in the supernatant. Cytosolic activity probably was due 
to microsomal leakage during homogenization. Eighty percent of the 
enzymatic activity was recovered from the gradients. 
No real differences in enzymatic activities and gradient distributions 
between castrated males and females were found (P>.10, data not shown). 
The castrated males were included in this study because of limited access 
to porcine liver tissue. Since no differences existed, all data were pooled 
in order to obtain better estimates of population means. 
Aldehyde Dehydrogenase 
Our results from pig liver demonstrate that the high isozyme 
occurred in three major peaks corresponding to densities of the 
peroxisomal, mitochondrial, and cytosolic regions of the gradient (Figure 
1). The majority of the high ALDH activity occurred in the 
mitochondria (54.3%). Thirty-two percent of the activity existed in the 
peroxisomes, 8.3% in the ER, and 4.6% was found in the cytosol. We did 
not, however, find the high isozyme in the microsomes as has been 
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reported previously (23). This may be due to overlap of the cytosol with 
the ER^ or it may be the result of species differences. A large degree of 
variation was observed in the activity of the high isozyme in the 
cytosol and ER among livers used in this study. 
The low isozyme of ALDH sedimented as a single peak with 
NAD:glutamate dehydrogenase and mitochondrial P-oxidation. Sixty-nine 
percent of the total activity of this isozyme occurred in the mitochondrial 
band. Peroxisomes contained 8.0%, and the ER possessed 8.8%. The 
presence of this enzyme in the peroxisomes and ER can be accounted for 
through mitochondrial contamination. On two occasions, however, a 
distinct peak of low ALDH activity occurred in the peroxisomes, 
which could not entirely be accounted for through contamination of 
peroxisomes with mitochondria. Activity of the low ALDH also was 
present in the cytosol (14.3%). Thirty-five percent and 30% of the 
activities of the high and low isozymes, respectively, were 
recovered from the gradients. 
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TABLE I 
ACTIVITY"» '^' OF ENZYMES IN PORCINE HEPATOCYTE 
PEROXISOMES, MTTOCHONDRU, ENDOPLASMIC RETICULUM, 
AND CYTOSOL 
ENZYME 
Catalase 
PEROXISOME"» MrrOCHRONDRLV" ENDOPLASMIC'' 
RETICULUM 
10±1 3±1 1±0 
Glutamate 
Dehydrogenase 
43±8 161±4 5±1 
NADPH;Cytochrome 
c Reductase 
19±5 29±5 40±10 
Mitochondrial 
P-Oxidation 
1±1 10±1 0 
Peroxisomal 
P-Oxidation 
36±6 1±1 0 
Aldehyde 
Dehydrogenase 
(high K J 
30±1 33±7 4±3 
Aldehyde 
Dehydrogenase 
(low KJ 
4±4 23+3 2±2 
a average of 6 livers 
b units/mg protein 
c mean enzymatic rates for porcine liver. Areas under the 
gradients were summed and adjusted to 100% of homogenate 
values 
I 
43 
TABLE I (CONTINUED) 
ACTIVITY"'''^  OF ENZYMES IN PORCINE HEPATOCYTE 
PEROXISOMES, MITOCHONDRIA, ENDOPLASMIC RETICULUM, 
AND CYTOSOL 
ENZYME 
Catalase 
Glutamate 
Dehydrogenase 
NADPH;Cytochrome 
c Reductase 
Mitchondrial 
p-Oxidation 
Peroxisomal 
P-Oxidation 
Aldehyde 
Dehydrogenase 
(high KJ 
Aldehyde 
Dehydrogenase 
(low 
CYTOSOL"» TOTAL LIVER»» MEAN LIVER RATE": 
12±0 6±2 190±85 
8±4 35±14 1092±180 
4±5 
0 
3±00 
4±4 
40±10 
6±1 
6±1 
100±20 
35±16 
4±5 
137±39 
142137 
1818±88 
733±67 
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Relationstup Between Peroxisomal 3-oxidation and 
Mitochondrial tj-oxidation 
P-oxidation was assayed as the rate of palmityl-CoA-dependent 
oxygen consumption. The area under the curves for palmityl-CoA-
dependent oxygen consumption in the peroxisomes and mitochondria 
should indicate the relative capacities for each organelle to carry out (3-
oxidation (26). No palmityl-CoA-dependent oxygen consumption could be 
detected in the peak mitochondrial fraction by using the peroxisomal 
assay. Likewise, no palmityl-CoA-dependent oxygen uptake occurred by 
using the peak peroxisomal fraction in the mitochondrial assay. 
The area for peroxisomal P-oxidation indicates an average capacity of 
142 ±38 nmoles O2 consumed/min x g liver (Table I). The average 
capacity for the surviving mitochondria was 137 ±39 nmoles 0^ 
consiimed/min x g liver. Thus, the ratio of peroxisomal P-oxidation to 
mitochondrial P-oxidation is 1. This assumes that all the mitochondria 
and peroxisomes were respiring in the assay. We made no attempt to 
optimize the assay conditions nor to determine if any of the cytosolic 
catalase was peroxisomal in origin. Since only 5.4% of the 
NAD: glutamate dehydrogenase activity was in the supernatant, it seems 
likely that most of the mitochondria were intact. These results estimate 
only the maximal capacity for p-oxidation. The physiological rates 
occurring within the intact cell may be entirely different. 
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DISCUSSION 
The presence of acetyltxansferases in the peroxisome of porcine liver 
has been reported by Markwell and co-workers (27). Those authors 
indicated that the peroxisome may play a significant role in regulating 
carbon flow in the cell. The relationship between peroxisomal and 
mitochondrial P-oxidation was not reported, however, and the contribution 
of the peroxisome to carbon flow remained unknown. We have found that 
the porcine hepatocyte peroxisome is responsible for a significant amount 
of palmityl-CoA-dependent oxygen consumption. In the pig, the 
peroxisomal system may contribute significantly to the oxidation of 
palmitate. 
The relative contribution of the peroxisome to lipid metabolism has 
been established for very few species. Data in Table II present reports of 
peroxisomal p-oxidation activity in various species. The rates range from 
30 nmoles/min/g liver to 1766 nmoles/min/g liver. P-Oxidation in rats 
ranges from 280 to 1200 nmoles/min/g liver. Estimates of mouse P-
oxidation range from 280 to 468 nmoles/min/g liver. The lowest estimates 
reported are in Rhesus monkeys and Syrian golden hamsters. Syrian 
golden hamsters also were reported to possess one of the highest activities 
per milligram of protein. The use of a light mitochondrial fraction instead 
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of liver homogenates may account for the anomalously high activities. 
Our findings for the porcine hepatocyte are similar to the estimates 
presented for humans. 
Strain and sex differences may exist as well. A 2 -to 3-fold difference 
in peroxisomal P-oxidation activity between the lean C57BL/6J mouse and 
ICR mice has been reported (25). Differences in the ratio of 
mitochondrial to peroxisomal p-oxidation between males and females have 
been reported (20.25). It seems that tlie contribution of the peroxisome to 
cellular carbon flow may differ physiologically among different strains 
within a species, between sexes, and among species as well. Comparison 
of our data from swine to that reported for rodents supports the contention 
that, at the very least, species differences exist. 
We have demonstrated the presence of an aldehyde dehydrogenase 
with a high for acetaldehyde in the porcine hepatocyte peroxisome. 
The presence of ALDH with a high toward acetaldehyde in the 
cytoplasm, mitochondria, microsomes, and the peroxisome of the rat has 
been reported previously (23,28,29). We have found two isozymes of 
ALDH to be present in porcine liver. The distribution of both isozymes of 
ALDH in porcine hepatocytes is similar to what has been reported in the 
rat except for our inability to discern a distinct peak of the high 
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isozyme in the ER. Total enzymatic activity seems to be veiy similar 
also. Total rat liver low ALDH activity ranges from 2.1 to 7.6 nmoles 
NAD reduced/min/mg protein. Total enzymatic activity for the high 
isozyme varies from 3.3 to 34.1 nmoles NAD reduced/min/mg protein. 
Peroxisomal high activity has been reported to be 34.5 nmoles/min/mg 
protein (16,30). These results are similar to what we report in porcine 
liver (Table I). 
The function of ALDH in the peroxisome may be detoxification. 
ALDH converts aldehydes into more water-soluble carboxylic acids, which 
could contribute to shorter half-lives of reactive aldehydes in the cell. 
Aldehydes, epoxides, and other lipid oxidation products may contribute to 
the development of the hepatocellular carcinomas (13). Species 
differences in the response of ALDH to peroxisome proliferation, as well 
as in the abiity ofALDH to clear aldehydes, may exist. Interspecies 
variation in aldehyde metabolism and peroxisomal/mitochondrial (3-
oxidation ratios may explain the variation in susceptibilities to develop 
hepatocellular carcinomas during long-term treatment with peroxisome 
proliferators. ALDH has been reported to be inducible in the rat during 
treatment with peroxisome proliferators and may occur in response to the 
increased oxidizing conditions caused through peroxisomally produced 
H2O2. ALDH may also contribute reducing equivalents and carboxylic 
48 
acids for P-oxidation. Correlation of peroxisomal ALDH activity to 
peroxisomal P-oxidation rates and catalase activity may lend insight into 
the function of these enzymes in the organelle. 
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TABLE II 
RELATIONSHIP OF HEPATOCYTE PEROXISOMAL B-OXIDATION" 
AMONG SPECIES 
SPECIES P-OXIDATION RATE SP. ACT" REFERENCE 
Rat^CFischer F344, Female) 800 11 
Raf: 810150 31 
Rat^ 280 20 
Rat°(male Wistar) 585±178 32 
Rat'^(6 wk old male Wistar) 660120 5.80011.100 33 
Rat®(27 wk old male Wistar) 430±111 4.04011.240 33 
Rat®(male Wistar) 380±110 34 
Rat®(male Wistar) 840141 1.4410.07 35 
Rat®(male F344) 120010300 36 
Syrian Golden Hamster^^(male) 106.7115.4 9 
Syrian Golden Hamster^(male) 30110 37 
Mouse®(lean) 2631143 9.3 25 
Mouse°(obese) 468159 25 
Mouse®(DDY Strain) 17661307 32 
Pigeon® 3801130 7 
Chicken® 300120 7 
Cat® 450110 7 
Cynomolgus Monkey® 5701120 7 
Rhesus Monkey 140130 7 
Human Biopsy® 240160 31 
° Rates are reported for non-drug treated control groups. 
'' Reported as nmoles NAD reduced/min/mg protein. 
° Rate reported as nmoles NAD reduced/min/g liver. 
^ Rate reported as nmoles Og consumed/min/g liver estimated from figure. 
° Rate reported as soluble acyl CoA released/mim/g liver. 
^ NADH was estimated using rezazurin and NADH oxioreductase. Rates 
Were determined in an enriched peroxisomal fraction. 
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PART II. 
EFFECTS OF CLOFIBRIC ACID ON ISOLATED PORCINE 
HEPATOCYTES: A NON-RODENT MODEL FOR THE STUDY OF 
PEROXISOMAL METABOLISM 
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ABSTRACT 
The effects of clofibric acid on primary porcine hepatocytes from 6-
month-old female Yorkshire hogs were investigated. Isolated hepatocytes 
were exposed to clofibric acid concentrations ranging from 0 to 3.0 mM. 
Catalase, NAD:glutamate dehydrogenase, mitochondrial p-oxidation, and 
peroxisomal p-oxidation were not affected in the range of drug 
concentrations used in this study. Drug treatments resulted in a 40% 
increase in cellular protein, a 900% increase in NADPHicytochrome c 
reductase, a 600% increase in high and low isozymes of aldehyde 
dehydrogenase (ALDH), and a 40% increase in superoxide dismutase 
(SOD) activity. Regression analysis of enzyme activity and protein 
content onto drug concentration was significantly quadratic for all 
increases. The response of the low isozyme of ALDH had a threshold 
at 0.37 mM clofibric acid. Separation of organelles by isopynic sucrose-
gradient ultracentrifugation resulted in a distinct peak of SOD activity in 
the peroxisomal region of the gradients. Peak SOD activity corresponds to 
the peroxisomal markers and was found to be approximately 70 standard 
SOD units/ml gradient. Contamination of peroxisomes with mitochondria 
did not account for the presence of SOD in the isolated peroxisome. 
Interspecies differences in metabolism are discussed. 
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INTRODUCTION 
Peroxisome metabolism and proliferation have been extensively 
studied in rodents. Although data exist on the distribution, composition, 
and response to environmental stimuli of the organelle in rats and mice, 
little information can be found for other mammalian species. In addition, 
the enzymatic profile of the organelle within a species can vary, depending 
on the tissue examined and substrate availability (1,2,3). It is evident that 
treatment with peroxisome-modulating drugs may not have the same 
effects in all species nor all tissues (4,5). Thus, interspecies variation in 
peroxisomal metabolism seems likely. 
The void in interspecies metabolism data is of concern. Treatment of 
rodents with several structurally diverse xenobiotics results in the 
proliferation of peroxisomes and the induction of selected peroxisomal and 
non-peroxisomal enzymes (4). Long-term treatment of rodents with these 
agents results in the development of hepatocellular carcinomas and has 
prompted the theory that peroxisome proliferators, as a class, are 
carcinogenic (6). Structurally diverse agents such as di-(ethyhexyl) 
phthalate, phenoxyacid herbicides, acetylsalicyclic acid, valproic acid, and 
various hypolipidemic drugs are peroxisome proliferators (7-11). Some of 
these chemicals are widespread contaminants of the environment (12). 
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The lack of interspecies metabolism data, coupled with the observation of 
proliferation in some species, absence in others, or occurrence only at 
unacceptably high dosages, raises questions concerning the application of 
rodent data to the risk assessment of peroxisome proliferators 
(4,11,13,14). 
One must question whether the contribution of the organelle to 
metabolic homeostatis differs among species. In rodents, various 
nutritionally-related states alter peroxisomal metabolism. States such as 
prolonged fasting, high-fat diets, and vitamin E deficiency result in 
peroxisome proliferation (15-17). Little is known about peroxisomal 
metabolism other than in rodents. We previously demonstrated that the 
capacity of the peroxisome to contribute to cellular P-oxidation is much 
greater in the pig than in the rat. The maximum capacity to carry out (3-
oxidation in the peroxisome is approximately 5 times lower for porcine 
liver than the rat. Rates which we obtained from porcine liver are more 
similar to human liver (18). What seems clear is that detailed data on 
peroxisomal metabolism in species other than the rat and mouse are 
needed. These data will help in unraveling the metabolic role of the 
organelle in the cell. 
We have undertaken this study to evaluate the use of porcine cell 
culture in the study of peroxisomal metabolism. Porcine liver is a 
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convienent source of tissue to researchers and possibly a better model for 
human metabolism than is rodent liver. Porcine tissue can be collected 
from local slaughter operations and cultured in vitro. The in vitro model 
can be used to study the effects of xenobiotics on peroxisomal 
metabolism. We have attempted to determine the sensitivity of P-
oxidation to peroxisome proliferators for porcine hepatocytes grown in 
culture. We are also interested in ascertaining what differences exist, if 
any, in selected detoxification pathways associated with the peroxisome. 
We have chosen clofibric acid since clofibrate is hydrolyzed to clofibric 
acid by esterases in the digestive tract and the blood. 
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MATERIALS AND METHODS 
Tissue Dissociation 
Porcine liver was obtained from 6-month-old female Yorkshire hogs. 
Livers were removed within 30 minutes post-mortem as soon as the body 
cavity was opened. Livers were handled aseptically. The central lobes of 
the livers were dissected free and placed in a sterile hood for further 
processing. 
The tissue was dissociated by using a three-step procedure similar to 
that described by Seglen (19). Livers were first perfused for 4 minutes 
with a calcium magnesium-free balanced salt solution (19). The medium 
was modified to contain 0.5 mM EGTA and 1 g/L D-glucose. Perfusion 
was carried out using a large central vein. The tissue was then perfused 
with approximately 100 ml of the suspension solution (BSS), described by 
Seglen, to remove remaining EGTA from the tissue. This was followed 
by perfusing with a digestion buffer for 25 minutes. The digestion buffer 
of Seglen was modified to contain 0.12% collagenase (type I, Sigma 
Chemical Co.), 125 mg/L taurine, 910 mg/L mannitol, and 1 g/L D-
glucose. The buffers were maintained at 37°C throughout the perfusion. 
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Perfusion was conducted by using a peristaltic pump maintained at a rate 
that kept the liver tissue firm. Liver effluent was collected, filtered 
through cheesecloth, gassed with oxygen, and reperfused by using a sterile 
apparatus. 
Upon completion of the perfusion, the tissue was scissor-minced and 
placed in 100 ml of Hams F-12 medium (Sigma Chemical Co.) with 
0.10% collagenase for an additional 10 minutes. Gentle shaking was 
applied to dislodge the cells. The resulting cell suspension was placed on 
ice and filtered through cheesecloth to remove tissue debris and cell 
clumps. The cell suspension was then centrifuged at 50 a: g for 2 minutes, 
resuspended in BSS and pelleted as above. The pellet was washed once 
more with Hams F-12 medium containing 25% fetal calf serum suspended 
in the equilibration medium, counted, and plated to a density of 2.5 x 10^ 
viable cells/ dish (60 x 15 mm Falcon cell culture dish). Viability was 
determined by trypan-blue dye exclusion. 
Culture Conditions. 
Cells were equilibrated in a 95%/5% oxygen/carbon dioxide 
atmosphere at 37°C. Equilibration medium consisted of Hams F-12, pH 
7.5, supplemented with 25% fetal calf serum, 125 mg/L taurine, 8.3% 
brain heart infusion (Difco Laboratories), 910 mg/L mannitol, 50 mg/L L-
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ascorbic acid, 460 mg/L Na pyruvate, lO'"^ M hydrocortisone, 10"^ M 
insulin, and 122 mg/ L additional L-glutamine. The cells were 
equilibrated in the incubator for 4 hours post-isolation whereupon the 
medium and dead cells were removed. Treatments were initiated at this 
time in a medium similar to that described above, but containing only 10% 
fetal calf serum, pH 7.5. Media and solutions were sterilized by filtration 
through a 0.2 micron filter. All solutions contained 60 units/ml penicillin 
base, 100 mcg/ml streptomycin sulfate, and 0.25 mcg/ml Fungizone 
(Gibco Laboratories). 
Drug Treatments 
Treatments consisted of a no-drug control, 0,19 mM, 0.37 mM, 0.75 
mM, 1.5 mM, and 3.0 mM clofibric acid (Na salt). Clofibric acid was 
dissolved in distilled water and added to the medium immediately prior to 
begirming the treatments. The experiment was replicated 5 times. Cells 
were exposed to the drug for 72 hours. Medium was changed at 24 hour 
intervals. Lactate dehydrogenase release into the medium was monitored 
over the duration of 2 of the replications. At the end of the treatments, 
the plates were washed 2 times with ice-cold BSS. The cells were 
detached from the plates by using a rubber policeman and centrifuged at 
50 X g for 2 minutes. Cells were resuspended in a homogenizing buffer 
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consisting of 20 mM MOPS, pH 7.4, 0.25 M sucrose, and 0.10% ethanol. 
Cells were homogenized with a motor-driven teflon Potter-Elvehjem 
homogenizer. The resulting homogenate was centrifuged at 750 ^ ^ for 10 
minutes to remove debris. All operations were carried out on ice. Catalase 
and P-oxidation activities were determined immediately after isolation. 
The remaining homogenate was stored at -20°C until needed. 
Statistical analysis was conducted using the General Linear Models 
procedure of SAS (20). T-tests were used where appropriate. 
Enzyme Assays 
Catalase (EC 1.11.1.6) activity was assayed immediately after 
homogenization as in (21). Units correspond to fxmoles HjOj 
consumed/minute. NAD:Glutamate dehydrogenase (EC 1.4.1.2) activity 
was assayed (22) with 55 ng/ml antimycin A and 5 ng/ml rotenone 
included in the buffer to inhibit NADH oxidase. Units correspond to 
mmoles NAD reduced/min. NADPH:Cytochrome c reductase (EC 
1.6.99.3) activity was assayed as in (23). Units correspond to nmoles 
cytochrome c reduced/min. Lactate dehydrogenase (LDH; EC 1.1.1.27) 
activity was assayed (24) in 80 mM Tris-HCL, final concentration. 
Medium was dialiyzed overnight at 4°C against the assay buffer before 
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use. Superoxide dismutase (SOD; EC 1.15.1.1) activity was assayed as in 
(25). SOD units are reported as amount of protein, in mg, to inhibit 
cytochrome c reduction by 50%. The high and low isozymes of 
aldehyde dehydrogenase (ALDH; EC 1.2.1.5 and EC 1.2.1.3) were assayed 
as reported by Koivula and Koivusalo (26). The assay buffer was 
modified to contain 0.1% bovine serum albumin and 0.1% Triton X-100. 
Assays were monitored over a 48-hour period against a blank at 4°C. The 
blank reaction was similar to the above but contained no aldehyde. The 
substrate concentration for the high isozyme was 5.0 mM acetaldehyde 
and 0.05 mM acetaldehyde for the low isozyme. Units correspond to 
nmoles NAD reduced/min. 
Mitochondrial p-oxidation activity was assayed (27) as palmityl-CoA-
dependent oxygen consumption by using a Clark-type electrode at 35°C. 
The oxygen concentration of air-saturated water was taken to be 231 |iM 
(28). The procedure was modified to include 100 jiM ATP, and 0.5 mM 
DL-(+)-camitine. Units correspond to nmoles O^ consumed/ min. 
Peroxisomal P-oxidation (28) activity was recorded as immoles oxygen 
consumed using a Clark-type electrode as above. The assay mixture was 
modified to contain 22 ng/ml antimycin A instead of KCN. Units 
correspond to nmoles Og consumed/min. 
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Ornithine transcarbamylase (EC 2.1.3.3) activity was assayed as reported 
(30). . 
Protein concentration was determined using the method of Lowry et 
al. (31). 
Isopynic Sucrose Density Centrifugation 
Intact liver tissue from 3 Yorkshire female pigs, age 6-months, was 
taken as described in tissue preparation. The tissue was immediately 
perfused with ice-cold homogenizing buffer which consisted of 20 mM 
MOPS pH 7.2, 0.25 M sucrose, and 0.10% ethanol. The tissue was 
scissor-minced, diluted 1:10 (W/V) with the homogenization buffer, and 
homogenized with 1-stroke of a motor-driven teflon Potter-Elvehjem 
homogenizer at 100 RPM. The homogenate was then filtered through 
cheesecloth and centrifuged at 750 % g at 4°C in order to remove nuclei 
and cell debris. The post-nuclear supernatant was layered onto a 
nonlinear sucrose gradient, ranging in density (20°C) from 1.08 to 1.28 
g/ml. Gradients were prepared 24 hr. before use. Centrifugation was 
carried out at 105,000 x g for 3.5 hours using a Beckman Ti28 rotor and a 
Beckman L-2 ultracentrifuge. At the completion of the run, the gradients 
were collected in 1-ml fractions and assayed as described. 
64 
TABLE I 
Comparison of Enzyme Parameters* between Intact Tissue and 
• Isolated Hepatocvtes 
ENZYME 
Catalase 
Glutamate 
dehydrogenase 
Mitochondrial 
p-oxidation 
Peroxisomal 
P-oxidation 
Aldehyde 
dehydrogenase 
(high K J 
Aldehyde 
dehydrogenase 
(low KJ 
NADPHxytochrome 
c reductase 
Superoxide 
dismutase 
Ornithine 
transcarbamylase 
INTACT TISSUE ISOLATED HEPATOCVTES 
6±2 mmole 
35±14 nmole 
6±1 nmole 
6±2 nmole 
101±20 nmole 
35±I6 nmole 
34±6 nmole 
70±5 unit 
N.A. 
615±29 ^mole 
31±3 nmole 
5±2 nmole 
8±1 nmole 
74±8 nmole 
59±9 nmole 
10±1 pmole 
7±2 units 
53 p.mole 
a Activities are expressed per mg protein/min. Assay methods are 
described in methods section. 
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RESULTS 
Viability and Culture Characterization 
Cell viability was determined immediately post-isolation by trypan-
blue dye exclusion. Viability routinely ranged between 80-97%. Any 
amount of dye uptake was taken to be a sign of cell death. Cells attached 
to the plates within four hours after isolation. Morphologically, cells were 
large, appeared pleomorphic, and were epithelial in nature. Distinct cell 
membranes and nuclei could be seen. Cytoplasm tended to appear slightly 
granular. A number of binucleated cells were randomly distributed 
throughout the cultures. 
Lactate dehydrogenase (LDH) release into the medium was monitored 
over the 72-hour culture period for 2 of the replicates (data not shown). 
After the first medium change, LDH activity in the medium decreased to 
low levels (180 nmoles NAD reduced/min/ml medium) and remained 
constant throughout the culture period. Drug concentration did not affect 
LDH release into the medium. Under standard culture conditions, cell 
division did not occur although random colonies could occasionally be 
observed. Cell division could be stimulated with 25% fetal calf serum and 
20 ng/L liver cell growth-factor (glycyl-L-histidyl-L-lysine) (32). After 72 
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hours, random colonies of 40-50 cells could be seen. Cultures never grew 
to confluency, however. Ornithine transcarbamylase activity was high 
(Table 1). These data indicate that, although the cultures were 
heterogeneous, most of the cells were parenchymal and viable. 
Comparison of Intact Liver and Isolated Hepatocytes 
Activities of selected enzymes were determined in intact porcine liver 
and isolated cells not exposed to clofibric acid (Table 1). Data are 
expressed per milligram of protein. Total catalase activity was less in the 
isolated cells. This result is somewhat perplexing. Catalase activity may 
be decreasing as a result of culture aging, or it may have been 
overestimated initially due to residual red blood cell catalase. 
NAD:Glutamate dehydrogenase activity, the mitochondrial marker enzyme, 
was similar for both the intact tissue and isolated cells. P-Oxidation for 
both the peroxisomal and mitochondrial pathways were similar both in 
vivo and in vitro. Aldehyde dehydrogenase rates were also similar 
between the intact tissue and isolated cells. NADPH:Cytochrome c 
reductase activity decreased in the isolated cells, as did the SOD activity. 
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Effects of Clofibric Acid on the Enzymatic Activity 
in Isolated Hepatocyte Organelles 
Isolated hepatocytes were exposed to clofibric acid concentrations 
ranging from 0 to 3.0 mM. Concentrations were selected to represent 
those used in studies utilizing isolated rodent hepatocytes (33). Rates are 
expressed as % of control rates/10® cells. 
Figure la portrays the response of catalase to treatment with clofibric 
acid. Catalase activity was not affected by any of the treatments. 
Treatment means did not differ significantly (P>.52) from the control and 
the slope of the regression was not significantly different from zero 
(P>.75). 
NAD:Glutamate dehydrogenase activity was not affected either (Fig. 
lb). No significant (P>.64) differences existed amoung treatments and the 
slope of the best-fit regression was not different from zero (P>.76). A 
slight decreasing trend is visible. This was caused by high GDH activity 
at the low drug dosages in one replicate, possibly a result of 
contamination. 
Clofibric acid did effect changes in total cell protein, however (Fig. 
Ic). Drug treatment resulted in a 40% increase in cellular protein. 
Figure 1. Effect of clofibric acid. All rates expressed as % of control 
rate/10^ cells. Assay methods described in materials 
and method section, (a) Catalase activity. Mean control rate 
=35.41 ±6.95 (imoles/min/10^ cells, (b) NAD:Glutamate 
dehydrogenase activity. Mean control rate =16±4 
nmoles/min/10^ cells. 
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Figure 1 (continued), (c) Protein content. Mean control rate = 485±239 
|Xg protein/10^ cells, (d) NADPH:cytochrome 
c reductase. Mean control value = 7±4 nmoles 
cytochrome c reduced/min/lO^ cells. 
Assay methods are described under Materials and 
Methods. 
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A significantly quadratic (P>.01) response existed that appeared linear to 
0.37 mM. Maximal protein content occurred at the 0.75 mM level and 
remained constant at the higher dosages. 
Most of the increase in protein was probably due to induction of the 
microsomes as depicted in Figure Id. NADPHiCytochrome c reductase 
activity, a marker for microsomes, was dramatically induced by clofibric 
acid treatment. The response was significantly (P>.01 ) quadratic with an 
increase of 900% over that of the control. A plot of the rates expressed 
per mg protein is similar to the rates expressed per 10^ cells indicating the 
activity is not being diluted by induction of other proteins in the cell (data 
not shown). 
The response of peroxisomal and mitochondrial P-oxidation to 
clofibric acid will indicate the sensitivity of the pathways to clofibric acid. 
These responses are shown in Figures 2a and 2b, respectively. 
Mitochondrial P-oxidation is not affected in the range of drug 
concentrations used in this study. No significant (P>.66) induction 
occurred. The best-fit regression was linear but the slope was not different 
from zero (P>.26). A slight increasing trend can be seen which is 
probably due to anomalous behavior by one replicate. Likewise, 
peroxisomal P-oxidation activity is not affected by clofibric acid as no 
significant differences (P>.72) were found amoung the treatments. 
Figure 2. (a) Peroxisomal p-oxidation activity and (b) mitochondrial 
p-oxidation as influenced by clofibric acid treatment for 5 
representative replicates. Content expressed as % of control 
value/min/10^ cells. Mean control value = 7±6 
nmoles Oj consumed/min/10^ cells for peroxisomal 
activity and 5±1 nmoles Oj consumed/min/10® cells 
for mitochondrial activity. Assay method described in Materials 
and Methods section. 
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Figure 3. Distribution of superoxide disutase activity through 
a sucrose gradient for a representative replication. 
Organelle location, identified through enzyme markers, 
are: (a) catalase for peroxisomes, (b) glutamate 
dehydrogenase for mitochrondria, (c) mitochondrial 
P-oxidation, and (d) NADPHicytochrome c reductase 
for microsomes. Assay methods described in Materials 
and Methods section. 
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Figure 4. Superoxide dismutase activity as influenced by clofibric acid 
treatment. Content expressed as % of control value/min/10^ 
cells. Mean control value = 31±7 units/10^ cells. Assay 
method is described in Materials and Methods section. 
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These data indicate porcine peroxisomal P-oxidation is insensitive to 
clofibric acid. In rodents, a 4- to 30-fold increase in activity can be 
expected in the range of drug concentrations we have chosen. One 
replicate did show an increase in activity at the 0.19 mM level but was not 
reproducible. 
Separation of organelles by isopynic sucrose-gradient 
ultracentrifugation is depicted in Figure 3. Distribution of the marker 
enzymes catalase for peroxisomes, GDH for mitochondria, and 
NADPH:cytochrome c reductase for microsomes shows that adequate 
resolution of the organelles was obtained. A distinct peak of SOD activity 
can be seen in the peroxisomal region of the gradient (10% of total SOD 
activity) with maximal activity corresponding to that of catalase and 
peroxisomal P-oxidation. Peroxisomal SOD activity was found to be 
approximately 70 units/ml gradient. Contamination of peroxisomes with 
mitochondria did not account for all the activity of SOD found in the 
peroxisomal region of the gradient. Thus an isozyme of SOD seems to be 
present in the organelle. Organelle separations were carried out on intact 
liver tissue becaus we were unable to obtain enough material from the cell 
cultures to perform organelle isolations. Enzymatic activity was very low 
in the gradients because of dilution of the peroxisomal SOD isolated from 
the porcine cell cultures. We were able to measure SOD activity in the 
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homogenates of the cultured cells, however, which is depicted in Figure 4. 
Figure 4 presents the response of SOD activity to treatment with 
clofibric acid. A significantly (P>.05) quadratic response occurred with 
maximal activity approaching 150% of that of the controls. We have not, 
as yet, ascertained which SOD isozyme is being induced as we were 
unable to measure SOD activity in the organelles isolated by isopynic 
sucrose ultracentrifugation. 
Aldehyde dehydrogenase activity is depicted in Figures 5a and b. 
Significant induction (P>.05) occurred for both the high and low 
variants. The response of the low isozyme shows a threshold value at 
0.37 mM clofibric acid. The response was linear from 0.37 to 1.5 mM. 
A decrease in activity occurred at the highest drug dose. The cells may be 
expressing a biochemical lesion indicating a toxicity at this level. A 
similar response can be seen for the high isozyme (Fig. 5b). A 
significant quadratic response occurred (P>.04), although no threshold was 
observed. Response to the drug was linear to 0.37 mM clofibric acid. 
The decrease in activity at the 3.0 mM dose level is probably an 
expression of cell toxicity. 
Figure 5. Response of the (a) low and high isozyme 
of aldehyde dehydrogenase as influenced by cloflbric acid treatment. 
Contents expressed as % pf control value/min/lO*^ cells. 
Mean control value low = 11±12 fmoles/min/10^ 
cells. Mean control value high = 29±17 fmoles/min/10® 
cells. Assay methods described in Materials and Methods section. 
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DISCUSSION 
The extrapolation of rodent-generated data on peroxisome proliferators 
to man has been questioned for some time. Species variation in 
peroxisomal metabolism seems likely, supporting evidence is limited, and 
the scope of the phenomena is incompletely understood. We believe that 
this is due to a lack of adequate non-rodent models to study peroxisome 
metabolism. Porcine hepatocyte peroxisomal and mitochondrial (3-
oxidation is not induced by up to 3.0 mM clofibric acid. Isolated rat cells, 
treated in a similar fashion respond with a dramatic increase in 
peroxisomal P-oxidation of up to 2900% (33,34). In rat hepatocyte cell 
culture, clofibric acid causes an induction of catalase activity, 
m • . 
approximately 1-2 fold, which, again, did not occur in the present study. 
Recently, variation in the kinetics of the response of cyanide-insensitive 
P-oxidation to a peroxisome proliferator (trichloroacetic acid) has been 
reported between intact rats and mice, with rats being more sensitive to 
trichloroacetic acid than mice (35). The difference in kinetics existed in 
isolated hepatocytes as well. Human hepatocyte peroxisomal P-oxidation, 
in the same study, was totally insensitive to trichloroacetic acid. One may 
conclude that the liver tissue of phylogenetically higher animals may be 
less sensitive to peroxisome proliferators than are rodents. 
84 
Specificities in metabolism may occur via a number of different 
mechanisms. Sensitivity to peroxisome proliferators may arise through 
receptor-mediated processes. Evidence in rats of a cytosolic protein 
receptor for nafenopen has been reported (36). Evidence also exists in rats 
for a clofibrate-induced inhibition of adenylate cyclase (37). These effects 
may be due to intrinsic differences in the type or number of receptors 
present in hepatocytes for these agents. Factors affecting bio-availability 
may be involved as well, although the ability to demonstrate kinetic 
differences in the response of isolated liver cells to peroxisome 
proliferators indicates factors at the cellular level are involved (35). 
Species specificities in the ability to invoke detoxification mechanisms 
may exist. These may occur either in the ability to deal with oxidative 
stress or to clear xenobiotics. The behavior of these enzymes in response 
to insult with clofibric acid will help indicate how the cells deal with the 
effects of the drug. If a state of oxidative stress exists, these enzymes 
may dissipate reactive intermediates, preventing toxicity. Although 
peroxisomal p-oxidation is not affected, other oxidases in the cell may be. 
The existence of a peroxisomal SOD has not previously been confirmed. 
SOD exists in association with the capacity to generate oxygen radicals in 
other regions of the cell. It seems logical that it would exist in the 
peroxisome which we have demonstrated. 
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We have also shown that total cellular SOD seems to respond in an 
inverse manner to what has been reported for rodents treated with 
clofibrate (38). It may be significant, then, that decreased SOD activity 
was associated with enhanced peroxidative risk in the rodent (38). 
Aldehyde dehydrogenase in the peroxisome may clear reactive 
aldehydes from the organelle or provide substrate for P-oxidation by 
carboxylation of aldehydes. Aldehyde dehydrogenase with a high for 
aetaldehyde is inducible in rats, which we reproduced with porcine cells 
(39). However, the low isozyme was not inducible in the rat as it was 
in the porcine cells. At high drug concentrations, the activity of both 
ALDH's in the porcine cell decreased significantly, possibly indicating 
toxicity. This effect was not reported in rodents. 
Probably the most significant change seen in the porcine cells was the 
induction of NADPHxytochrome c reductase, reflecting proliferation of 
the endoplasmic reticulum. It is well known that, in rodents, clofibric acid 
induces proliferation of the smooth endoplasmic reticulum (4). This 
probably occurred in our porcine cells as well. 
Porcine hepatocytes do respond to clofibric acid but in a manner 
distinctly different from than of rodents. An insensitivity to proliferation 
of peroxisomal enzymes and indications of toxicity at high dosages are 
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most obvious. Slight induction may occur at toxic levels, however, as 
occurred when guinea pigs were dosed with WY171883 which is also a 
peroxisome proliferator (40). 
A model more accurately reflecting human responses to peroxisome 
proliferators is needed so that we may gain a more complete understanding 
of the peroxisome's contribution to metabolism. The hypothesis that 
peroxisome proliferators are carcinogenic revolves around the ability of the 
peroxisomal oxidases to generate reactive species of oxygen. Because the 
ability to generate oxygen radicals is related to the metabolic activity of 
the peroxisomal oxidases, the inability to demonstrate induction of 
peroxisomal p-oxidation in tissues of the pig, human, and others probably 
suggests that the rodent model is invalid for extrapolation to other species. 
Our results support the claim that peroxisomal p-oxidation in higher 
animals is less sensitive to peroxisome proliferators than are rodents (40). 
From these data, it is reasonable to suggest that rodents are not appropriate 
models for the study of peroxisomal metabolism in higher animals. 
Porcine hepatocyte cell culture offers an alternative for the study of 
peroxisomal metabolism. 
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SUMMARY 
Peroxisomes are ubiquitous in nature. They have been demonstrated 
in many species and almost all cell types. Yet, after 30 years of study, 
their contribution to cellular metabolism still remains a mystery. The 
presence of a p-oxidation pathway, coupled with the capacity to 
metabolize cholesterol and generate ether glycerolipids, suggests an 
important role in lipid metabolism. This is further supported by the fact 
that several congenital anomalies involving alterations in, or complete 
absence of, peroxisomes are incompatible with life. The organelle must 
serve a purpose that enhances the survival of the cell. Whether the 
peroxisome plays a similar role with similar relative importance in all 
organisms, all tissues, and all cell types remains open to debate. This is 
because almost the entire spectrum of data on the peroxisome has been 
collected from relatively few species — the rat and mouse. 
Answering questions of interspecies differences in metabolism is 
important and quite relevant. Several peroxisome proliferating agents have 
been shown to be carcinogenic in rodents and it has been proposed that 
peroxisome proliferators, as a class, are carcinogenic. Does this apply to 
other species? Does the mechanism proposed to be responsible for the 
development of carcinomas in rodents after treatment with peroxisome 
proliferators also occur in other species? No answer is forthcoming. 
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Numerous examples of species-specific metabolism exist. Peroxisome 
metabolism may have its own specificities. Differing capabilities of an 
organism to respond to stimuli such as with sensitivity to peroxisome 
proliferators may exist such that peroxisome proliferation may occur in 
some species, be less dramatic in others, or be totally absent. Differences 
in ihe response of the peroxisome to peroxisome proliferators may arise 
through the presence or absence of receptors for the agents in the cells. 
Various species may differ in the ability to inactivate or detoxify 
chemicals modulating peroxisome numbers or peroxisomal enzyme 
activities. Species at different phylogenetic levels may have different 
subcellular distribution of enzymes associated with detoxification. One 
may question whether different animals differ in the ability of the cell to 
cope with the products of peroxisomal metabolism such as hydrogen 
peroxide, superoxide anions, or oxidized lipid components. Whole animal 
physiology may be important as well. All species do not possess similar 
modes of drug absorption, drug distribution, or drug elimination which 
may affect a species response to peroxisome proliferators. These factors 
must be dealt with before human risk can be determined for peroxisome 
proliferators. 
A better understanding of interspecies peroxisome metabolism is also 
relevant from the perspective of understanding metabolism in general. 
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What does the peroxisome contribute to the cell? How does it improve an 
organism's ability to survive? These are some of the questions we began 
to deal with in this work. Our purpose was to help elucidate the 
metabolism of the peroxisome in a species phylogentically removed from 
rodents. The two parts of this dissertation have described a non-rodent 
model for the study of peroxisome metabolism. 
In Part I, a peroxisome purification scheme was introduced which 
allowed for the demonstration of a porcine hepatocyte peroxisomal P-
oxidation pathway which has not previously been demonstrated. Through 
separation of the major organelles, we were able to demonstrate the 
presence of a peroxisomal P-oxidation pathway and estimate that the 
relative contribution of the peroxisome to whole cell p-oxidation was 50%. 
This finding differs from the 30% estimated for rodents. We were also 
able to show that, as in rats, the porcine hepatocyte peroxisome possesses 
an ALDH with a high for acetaldehyde. The relative distribution of 
the ALDH isozymes were similar to that reported for rats. A peroxisomal 
SOD was identified as well. ALDH and SOD may exist in the 
peroxisome to scavenge aldehydes and reactive forms of oxygen produced 
via the peroxisomal acyl-CoA oxidase. Superoxide dismutase has not 
been reported in the rodent peroxisome. 
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In Paît II of this dissertation, it was demonstrated that a peroxisomal 
SOD can be found in porcine liver. A protocol to isolate and grow 
porcine hepatocytes in culture was also described. This technique removes 
the need to maintain an animal herd and eliminates the disadvantage of 
using species larger than rodents as research tools. It offers the extra 
advantage of precise control of environment and the ability to manipulate 
the liver cells in a specific manner. Through this technique, we 
demonstrated that ALDH, NADPHicytochrome c reductase, and cellular 
protein content are inducible by clofibric acid concentrations in the 
millimolar range. Our most significant finding was that porcine hepatocyte 
P-oxidation, both mitochondrial and peroxisomal, is not inducible by 
clofibric acid. A 4- to 20-foId increase in peroxisomal P-oxidation can be 
expected in the drug concentrations used in this study when administered 
to rodents. 
These results demonstrate that a dramatic species-specific effect exists 
in the sensitivity of liver cells to clofibric acid. Our data show that 
porcine hepatocytes do respond to clofibric acid, but in a manner distinctly 
different from that of rodents. Porcine hepatocyte peroxisomal p-oxidation 
may be much less sensitive to this drug than is rodent liver. Our results 
are in agreement with the findings of others, who show a diminished or 
non-existent sensitivity to peroxisome proliferators in human liver cells 
and primates. We suggest that rodents are more sensitive to peroxisome 
proliferators than are phylogenetically higher animals and as such are a 
poor model for the study of the human peroxisome. Future studies in 
peroxisomal metabolism should focus on the elucidation of the phenomena 
of peroxisome proliferation and unraveling the metabolic role of the 
organelle in the cell. 
Porcine hepatocyte cell culture could be used to elucidate the nature of 
the increased sensitivity of rodents to these peroxisome proliferators and 
thus provide insight into the mechanism of peroxisome proliferation. 
Radiolabeled clofibric acid could be used to determine the presence and 
relative concentration of receptors for the drug in various cell types. 
Correlations should be made to determine if the presence of receptors is 
related to the ability to induce peroxisome proliferation. Kinetics of the 
binding of the drug to the receptor could also be determined and correlated 
to the ability to induce peroxisome proliferation. The receptors could be 
isolated and purified to help understand the nature of the receptor. The 
distribution and fate of clofibric acid in the cell should be studied also. 
Determination of the disposition of clofibric acid in the cell (i.e., is the 
drug internalized and what happens to it after binding?) is important to 
understanding the mechanism of proliferation. 
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The availability of a cell culture system suitable for the study of the 
». 
peroxisome allows for the use of specific metabolic inhibitors which can 
shunt energy substrates away from specific pathways without the death of 
the animal. These inhibitors could be used to see how the porcine 
hepatocytes deal with the loss of metabolic pathways as a means of 
understanding the peroxisome's contribution to metabolism. Metabolic 
intermediates can be quantified via freeze-clamp techniques which can be 
used to determine kinetic parameters of peroxisomal enzymes in situ. 
Radiolabeled substrates for energy metabolism can be administered to the 
cells to determine the fate of the intermediates as related to the 
peroxisome. These studies would add substantially to our understanding 
of interspecies peroxisomal metabolism and through it an understanding of 
human peroxisomal metabolism. 
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